ArticleLancet regional health. Americas2024
Simulation-based economic evaluation of the Wolbachia method in Brazil: a cost-effective strategy for dengue control.
Article in Lancet regional health. Americas, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The cost-effectiveness of Wolbachia-based biocontrol interventions for dengue: A scoping review of the available evidence.PLoS neglected tropical diseases · 2026Article
- The impact of large-scale release ofLancet regional health. Americas · 2026Article
- Ecological and engineered modulation of the mosquito microbiome: mechanisms, vector competence, and translational prospects for disease control.Frontiers in microbiology · 2026Review
- Integrating machine learning and time-to-event models to explain and predict risk of hospitalization due to dengue in Colombia.Scientific reports · 2025Article
- Long-Term Durability and Public Health Impact of City-WideTropical medicine and infectious disease · 2025Article
- ExploitingPathogens (Basel, Switzerland) · 2025Review
- Developing an eco-bio-social conceptual framework for dengue virus transmission in Latin America and the Caribbean: An e-Delphi study.PLOS global public health · 2025Article
- Trends in dengue incidence and lethality: interrupted time series analysis, Brazil, 2001-2022.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
- Article
- Dengue and severe dengue with neurological complications: a challenge for prevention and control.Arquivos de neuro-psiquiatria · 2024Review
- Cost-effectiveness of aLancet regional health. Americas · 2024Article
- Article
- The greatest Dengue epidemic in Brazil: Surveillance, Prevention, and Control.Revista da Sociedade Brasileira de Medicina Tropical · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dengue virus (DENV) is an arbovirus transmitted by Methods: We estimated the economic impact of implementing the Findings: Without Wolbachia, the model projected 1,762,688 reported dengue cases over 20 years. Implementing the Wolbachia method would avert at least 1,295,566 dengue cases, resulting in lower costs and greater effectiveness in all simulated cities. On average, for every 1000 inhabitants followed for 20 years, the Wolbachia method yielded a cost difference of USD 538,233.68 (BRL 2,691,168.40) and averted 5.56 DALYs. Net monetary benefits (NMB) were positive in all seven cities, ranging from USD 110.72 (BRL 553.59) to USD 1399.19 (BRL 6995.95) per inhabitant. Alternative scenarios have also shown a favourable return on investment with a positive benefit-cost ratio (BCR). Interpretation: Wolbachia is likely a cost-effective strategy in the Brazilian context, consistent with international studies. Sensitivity analysis and alternative scenarios confirmed the robustness of the results. Funding: This study was funded by the Wellcome Trust under a grant (224459/Z/21/Z).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.